Germano Di Sciascio

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7593977/germano-di-sciascio-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 137 5,995 75 h-index g-index citations papers 6,647 156 4.2 5.14 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
137	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. <i>Coronary Artery Disease</i> , 2021 , 32, 281-287	1.4	O
136	Non-INvasive Functional and Anatomic vascular evaluation for the prediction of coronary artery disease: The NINFA study. <i>International Journal of Cardiology</i> , 2021 , 322, 16-22	3.2	2
135	Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. <i>Cardiovascular Pathology</i> , 2021 , 54, 107362	3.8	1
134	Non-vitamin K oral anticoagulants at the time of cardiac rhythm device surgery: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020 , 188, 90-96	8.2	5
133	Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence. <i>European Journal of Internal Medicine</i> , 2020 , 77, 44-51	3.9	2
132	Acute Epstein-Barr related myocarditis: An unusual but life-threatening disease in an immunocompetent patient. <i>Journal of Cardiology Cases</i> , 2020 , 21, 137-140	0.6	8
131	Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 668-675	3.3	1
130	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , 2020 , 125, 757	1 <i>-</i> 3758	4
129	Characterization of inflammatory profile by breath analysis in chronic coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 675-681	1.9	1
128	Percutaneous Left Atrial Appendage Closure: Acute Effects on Left Atrial Pressure in Humans. JACC: Cardiovascular Interventions, 2019 , 12, 1089-1091	5	1
127	Changes of the coronary arteries and cardiac microvasculature with aging: Implications for translational research and clinical practice. <i>Mechanisms of Ageing and Development</i> , 2019 , 184, 111161	5.6	13
126	Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2019 , 18, 147	8.7	23
125	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. <i>American Journal of Cardiology</i> , 2018 , 121, 1027-1031	3	5
124	Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 496-503	5.1	7
123	Diabetes mellitus and atrial remodelling in patients with paroxysmal atrial fibrillation: Role of electroanatomical mapping and catheter ablation. <i>Diabetes and Vascular Disease Research</i> , 2018 , 15, 18.	5 ³ 1 ³ 95	9
122	Early prediction of contrast-induced acute kidney injury by a "bedside" assessment of Neutrophil Gelatinase-Associated Lipocalin during elective percutaneous coronary interventions. <i>PLoS ONE</i> , 2018 , 13, e0197833	3.7	15
121	Glycemic variability in the development of cardiovascular complications in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e3047	7.5	70

120	Antiplatelet therapy in valvular and structural heart disease interventions. <i>Cardiovascular Diagnosis and Therapy</i> , 2018 , 8, 678-693	2.6	6
119	Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Translational Research</i> , 2018 , 11, 517-523	3.3	19
118	Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018 , 41, 1476-1480	1.6	4
117	Should pre-operative left atrial volume receive more consideration in patients with degenerative mitral valve disease undergoing mitral valve surgery?. <i>International Journal of Cardiology</i> , 2017 , 227, 106-113	3.2	5
116	Platypnoea-orthodeoxia syndrome in the elderly: A difficult-to-make diagnosis of intracardiac right-to-left shunt. <i>Scottish Medical Journal</i> , 2017 , 62, 122-125	1.8	3
115	Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. <i>Clinical Research in Cardiology</i> , 2017 , 106, 69-75	6.1	23
114	Impact of the high-frequency cutoff of bandpass filtering on ECG quality and clinical interpretation: A comparison between 40Hz and 150Hz cutoff in a surgical preoperative adult outpatient population. <i>Journal of Electrocardiology</i> , 2016 , 49, 691-5	1.4	13
113	Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016 , 118, 980-4	3	9
112	Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). <i>Circulation</i> , 2016 , 134, 835-7	16.7	25
111	Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. <i>International Journal of Cardiology</i> , 2016 , 220, 629-33	3.2	24
110	Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. <i>American Journal of Cardiology</i> , 2016 , 118, 822-827	3	18
109	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). <i>American Journal of Cardiology</i> , 2016 , 117, 165-71	3	21
108	Large Ostium Primum Interatrial Septum Defect in Asymptomatic Elderly Patient. <i>Journal of Cardiovascular Echography</i> , 2016 , 26, 16-18	0.6	O
107	Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. <i>Europace</i> , 2015 , 17, 855-63	3.9	20
106	Hand-held echocardiography in the setting of pre-operative cardiac evaluation of patients undergoing non-cardiac surgery: results from a randomized pilot study. <i>International Journal of Cardiovascular Imaging</i> , 2015 , 31, 995-1000	2.5	4
105	Comparison among patients 15 years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents. <i>American Journal of Cardiology</i> , 2015 , 115, 1179-84	3	7
104	High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. <i>International Journal of Cardiology</i> , 2015 , 190, 124-5	3.2	9
103	Transapical closure of paraprosthetic mitral leak in a patient with inferior vena cava interruption and azygos continuation. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16 Suppl 1, S23-4	1.9	

102	Efficacy and Safety of Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in High-Risk Patients. <i>American Journal of Cardiology</i> , 2015 , 116, 1690-4	3	14
101	Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score. <i>Circulation: Cardiovascular Interventions</i> ,	6	7
100	Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. <i>Journal of Diabetes Research</i> , 2015 , 2015, 250201	3.9	11
99	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. <i>Interventional Cardiology</i> , 2015 , 7, 283-293	3	
98	Percutaneous Treatment of Recurrent In-Stent Restenosis of Carotid Artery Stenting: A Case Report and State-of-the-Art Review. <i>American Journal of Case Reports</i> , 2015 , 16, 558-62	1.3	9
97	Congenital Absence of Left Atrial Appendage in a Patient with Intracranial Hemorrhage. <i>American Journal of Case Reports</i> , 2015 , 16, 514-6	1.3	5
96	Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention 2014 , 207-219		
95	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. <i>European Heart Journal</i> , 2014 , 35, 2213-23b	9.5	55
94	Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2014 , 113, 1124-9	3	26
93	Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2014 , 174, 440-1	3.2	4
92	Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. <i>Circulation Journal</i> , 2014 , 78, 33-41	2.9	18
91	Prognostic role of platelet reactivity in patients with acute coronary syndromes. <i>Cardiology in Review</i> , 2014 , 22, 313-8	3.2	5
90	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. <i>Platelets</i> , 2014 , 25, 348-56	3.6	16
89	Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. Journal of Cardiovascular Translational Research, 2013 , 6, 346-54	3.3	2
88	Percutaneous closure of a pulmonary arteriovenous malformation in young patient with cryptogenic stroke. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, e26-7	5	4
87	Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). <i>American Journal of Cardiology</i> , 2013 ,	3	13
86	Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. <i>Journal of the</i>	15.1	48
85	American College of Cardiology, 2013 , 61, 1379-87 Stent thrombosis and platelet reactivity. Cor Et Vasa, 2013 , 55, e151-e157	0.3	

(2010-2013)

84	Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).	3	14
83	Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). <i>American Journal of Cardiology</i> , 2013 , 111, 1739-44	3	21
82	The protective effect of clopidogrel and atorvastatin in patients undergoing carotid stenting. <i>Interventional Cardiology</i> , 2013 , 5, 371-373	3	
81	Percutaneous closure of patent foramen ovale in a patient with situs viscerum inversus. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 168-70	1.9	
80	Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). <i>American Journal of</i>	3	47
79	Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during	3.2	3
78	A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.	5	69
77	Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2012 , 80, 377-84	2.7	13
76	High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized	15.1	75
75	Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during	15.1	97
74	Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. <i>Human Immunology</i> , 2011 , 72, 636-40	2.3	25
73	Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. <i>International Journal of Hypertension</i> , 2011 , 2011, 904742	2.4	7
72	Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction myocardial damage during angioplasty) SELECT substudy. <i>Journal of Cardiovascular</i>	1.9	1
71	Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). <i>American</i>	3	83
70	Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during	3	157
69	angioplastycontrast-induced nephropathy] trial. <i>American Journal of Cardiology</i> , 2011 , 108, 1-7 Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. <i>Circulation</i> , 2011 , 123, 1622-32	16.7	131
68	Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. <i>Future Cardiology</i> , 2010 , 6, 579-89	1.3	7
67	Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials. <i>Critical Pathways in Cardiology</i> , 2010 , 9, 19-22	1.3	4

66	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>European Heart Journal</i> , 2010 , 31, 1337-43	9.5	33
65	Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>Journal of the</i>	15.1	86
64	Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 128-34	2.7	5
63	Clinical benefits of statin pretreatment in patients undergoing coronary revascularization. <i>Clinical Lipidology</i> , 2010 , 5, 199-207		
62	Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. <i>Journal of Cardiovascular Medicine</i> , 2010 , 11, 795-800	1.9	13
61	Statin loading for acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2010 , 25, 373-8	2.1	8
60	Statins and their role in pre-percutaneous coronary intervention. <i>Current Cardiology Reports</i> , 2010 , 12, 295-301	4.2	7
59	Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2010 , 106, 619-23	3	65
58	Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 936	-42 ⁷	7
57	High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 35-40	5	55
56	Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 318-23	5	50
55	Identifying factors that predict the choice and success rate of radial artery catheterisation in contemporary real world cardiology practice: a sub-analysis of the PREVAIL study data. <i>EuroIntervention</i> , 2010 , 6, 240-246	3.1	26
54	A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. <i>EuroIntervention</i> , 2010 , 5, 976	5- <u>9</u> 80	
53	Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 413-20	5.1	8
52	Contemporary issues on clopidogrel therapy. Internal and Emergency Medicine, 2009, 4, 201-11	3.7	1
51	The use of functional tests and planned coronary angiography after percutaneous coronary revascularization in clinical practice. Results from the AFTER multicenter study. <i>International Journal of Cardiology</i> , 2009 , 137, 151-7	3.2	5
50	Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. <i>Journal of the American College of Continuo</i> 2000, 54, 550, 65	15.1	240
49	Cardiology, 2009, 54, 558-65 Giant left ventricular pseudoaneurysm complicating an acute myocardial infarction in patient with previous cardiac surgery: a case report. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 81-4	1.9	9

(2006-2008)

48	Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2008 , 101, 279-85	3	112
47	Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2008 , 102, 679-82	3	10
46	Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 2008 , 102, 1328-34	3	26
45	Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)	15.1	312
44	Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. <i>Atherosclerosis</i> , 2008 , 197, 588	s-9 <u>5</u> 51	10
43	Percutaneous coronary interventions and statins therapy. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008 , 2, 101-7	3.4	3
42	The risks and benefits of drug-eluting stents in the setting of STEMI. <i>Current Cardiology Reports</i> , 2008 , 10, 402-6	4.2	4
41	Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2008 , 71, 600-4	2.7	75
40	Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1272-8	15.1	366
39	The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons. <i>Fundamental and Clinical Pharmacology</i> , 2007 , 21 Suppl 2, 41-3	3.1	3
38	Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2007 , 100, 1199-206	3	96
37	Response to Letters Regarding Article, Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) Study[]Circulation,	16.7	2
36	Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. <i>Heart</i> , 2007 , 93, 598-600	5.1	25
35	Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. <i>American Heart Journal</i> , 2007 , 153, 749-54	4.9	98
34	Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. <i>Annals of Thoracic Surgery</i> , 2007 , 83, 1374-80	2.7	76
33	Dissecting intramyocardial hematoma masquerading as a pseudoaneurysm of left ventricular free wall: an unusual case of myocardial rupture. <i>Catheterization and Cardiovascular Interventions</i> , 2006 , 67, 724-7	2.7	5
32	Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. <i>Stroke</i> , 2006 , 37, 2400-9	6.7	83
31	Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. <i>Circulation</i> , 2006 , 114, 1455-61	16.7	493

30	Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules)	15.1	94
29	substudy. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1560-6 Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. <i>American Heart Journal</i> , 2006 , 151, 1215-22	4.9	51
28	Simvastatin reduces CD40 expression in an experimental model of early arterialization of saphenous vein graft. <i>Journal of Surgical Research</i> , 2006 , 136, 302-8	2.5	11
27	Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention: Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules)	15.1	83
26	Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. <i>Critical Care Medicine</i> , 2006 , 34, 660-7	1.4	176
25	Dexamethasone-eluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study. <i>Clinical Therapeutics</i> , 2005 , 27, 1411-9	3.5	13
24	Statins and percutaneous coronary intervention. <i>European Heart Journal</i> , 2005 , 26, 417; author reply 417-8	9.5	
23	Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. <i>Clinical Cardiology</i> , 2005 , 28, 193-6	3.3	21
22	Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2005 , 95, 502-5	3	29
21	Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2005 , 28, 805-10	3	36
20	Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. <i>Circulation</i> , 2005 , 111, 70-5	16.7	150
19	Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , 2005 , 111, 2099-10	16.7)6	552
18	Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , 2004 , 110, 674-8	16.7	386
17	Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. Journal of the American College of Cardiology, 2004 , 43, 35-8	15.1	34
16	High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1368-72	15.1	12
15	Role of Congenital and Acquired Thrombophilic Factors in the Failure of Thrombolysis in Patients with Acute Myocardial Infarction <i>Blood</i> , 2004 , 104, 2591-2591	2.2	
14	Plasma concentrations of interleukin-2 soluble receptor in mild ischaemic left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2003 , 5, 23-5	12.3	10
13	Coronary stenting in patients with depressed left ventricular function: acute and long-term results in a selected population. <i>Catheterization and Cardiovascular Interventions</i> , 2003 , 59, 429-33	2.7	22

LIST OF PUBLICATIONS

12	Pressure distension stimulates the expression of endothelial adhesion molecules in the human saphenous vein graft. <i>Annals of Thoracic Surgery</i> , 2003 , 76, 453-8; discussion 458	2.7	42
11	Intermittent warm blood cardioplegia induces the expression of heat shock protein-72 by ischemic myocardial preconditioning. <i>Vascular</i> , 2003 , 11, 367-74		9
10	Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2002 , 89, 372-6	3	50
9	Inflammatory markers and coronary interventions: a potentially useful follow-up modality after stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2002 , 56, 341-5	2.7	17
8	Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 139-43	5.1	29
7	Apoptosis and post-infarction left ventricular remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2002 , 34, 165-74	5.8	144
6	Early and long-term results of stenting of diffuse coronary artery disease. <i>American Journal of Cardiology</i> , 2000 , 86, 1166-70	3	23
5	Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. <i>Annals of Oncology</i> , 2000 , 11, 479-81	10.3	31
4	Midterm clinical and angiographic results of radial artery grafts used for myocardial revascularization. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998 , 116, 1015-21	1.5	158
3	Univentricular heart: an angiographic study. American Journal of Cardiology, 1982, 49, 787-94	3	17
2	Oral Antiplatelet Agents in PCI101-109		